by adminmps | Jun 17, 2022 | Clinical Trials, News, Research
Lysogene has just provided promising data from their clinical trials for the efficacy of Gene Therapy LYS-SAF302 in the treatment of MPS IIIA. Read Press Release >
by adminmps | Jun 17, 2022 | News, Resources
Titus and his family have made a series of videos to show what it’s like to grow up with Morquio (MPS IV). Find out more about Morquio Syndrome...
by adminmps | Jun 17, 2022 | News, Resources
Saving Ryan is the inspiring story by physician-scientist Dr. Emil Kakkis about his journey to develop a new, first-ever treatment for MPS. Hear about the great challenges getting grant and industry support for this rare disease despite the solid science behind doing...
by adminmps | May 26, 2022 | Clinical Trials, News, Research
The Canadian MPS Society met directly with Takeda Pharmaceuticals on May 11th, when Takeda shared with us that they will discontinue development of TAK-609, investigational intrathecal enzyme replacement therapy for MPS II, Hunter syndrome. Patients with MPS II...
by adminmps | Apr 29, 2022 | News, Resources
The Canadian MPS Society has been strongly advocating to add MPS I-H (Hurler Syndrome) to all newborn screening panels throughout Canada. To date, MPS I-H has been added to the Ontario Newborn Screening Panel, with the strong advocacy efforts of Newborn Screening...
by adminmps | Apr 29, 2022 | News, Resources
Ultragenyx has relaunched their patient support interactive website, UltraRareAdvocacy.com with a refreshed design and more ways to connect with rare disease communities. Visitors will find: More rare experiences from individuals and families living with...
